| OSM |
gene |
3 |
2 |
Oncostatin M, oncostatin M |
| OSMR |
gene |
3 |
2 |
Oncostatin M receptor |
| osteoarthritis |
phenotype |
2 |
2 |
OA |
| osteoporosis |
phenotype |
4 |
2 |
osteoporosis (T-score<−2.5) |
| Other |
phenotype |
7 |
1 |
Other race/ethnicity adolescents, undetermined |
| other drug dependence |
phenotype |
5 |
2 |
Drug dependence, other drug dependence, other drugs |
| other drugs |
drug |
25 |
9 |
drugs, maternal drug use, other drug use, other drugs, other substances, psychoactive drug |
| other drug use |
phenotype |
22 |
11 |
comorbid use and misuse of other drugs, drug use, illicit drug use, no other drug use, other drug use, other drugs, subsequent other illicit drug use |
| other psychiatric disorders |
phenotype |
5 |
3 |
OPD, other psychiatric disorders |
| other substances |
phenotype |
34 |
14 |
R-SD, history of other substance dependence diagnoses, number of lifetime other substance dependence diagnoses, other dependence diagnoses, other substance dependence diagnoses, other substance use, other substance use disorders, other substances, other substances in addiction, substance use disorders, substances other than alcohol, marijuana, and tobacco |
| OTX2 |
gene |
2 |
— |
|
| OUD |
phenotype |
8 |
7 |
DSM-5 Opioid Use Disorder, Opioid Use Disorder, opioid use disorder |
| our study |
cohort |
3 |
1 |
current study, this study |
| outcome |
phenotype |
27 |
14 |
O, better outcome, children's poor outcomes |
| outcome processing |
phenotype |
2 |
2 |
dysfunctional outcome processing |
| outcome-related negativity |
phenotype |
2 |
— |
ORN, feedback negativity, negativity |
| outlier |
phenotype |
2 |
— |
|
| outpatients |
cohort |
3 |
2 |
outpatients |
| ovarian cancer |
phenotype |
11 |
1 |
ovarian cancers, ovaries |
| overall health rating |
phenotype |
2 |
2 |
|
